Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
CoronaVac is safe and well tolerated in older adults. Neutralising antibody titresinduced by the 3 μg dose were similar to those of the 6 μg dose, and higher than…
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2021 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
Noosa News24 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
Noosa News24 hours agoAdvocates highlight sexual violence against older people, with Queensland elder abuse inquiry underway
-
Business23 hours ago3 steps to take to build a $1,000 monthly passive income
-
Business24 hours ago3 unstoppable ASX ETFs to buy and hold for 10 years